Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TdaP vaccine SSI
- Development stage
- Unknown
- Lead developer
- Statens Serum Institut
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
TdaP vaccine SSI is a trivalent biologic combination vaccine developed by the Statens Serum Institut (SSI) for booster immunization in adults. It is formulated to prevent infections caused by *Clostridium tetani*, *Corynebacterium diphtheriae*, and *Bordetella pertussis*. The vaccine contains tetanus toxoid, a reduced dose of diphtheria toxoid, and a unique monocomponent acellular pertussis antigen (pertussis toxoid). This specific formulation is designed to stimulate active immunity and provide a booster response in individuals previously primed with primary vaccinations. Clinical trials have evaluated its immunogenicity and safety compared to standard Td booster vaccines, particularly in adult populations previously vaccinated with whole-cell pertussis vaccines.
- Other names
- Tdap-Statens Serum Institut-tetanus-diphtheria-pertussisTdaP SSITetanus, Diphtheria and Mono Component Acellular Pertussis (TdaP) Vaccine
02
Targets
TT (Tetanus toxoid)
Beyond the preview
Go deeper on TdaP vaccine SSI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TdaP vaccine SSI.